CureVac Rallies On Interim Phase 1 Data For COVID-19 Vaccine Candidate: What You Need To KnowBenzinga • 11/10/20
CureVac's stock is up 8% as it shares additional Phase 1 data about its COVID-19 vaccine candidateMarket Watch • 11/10/20
CureVac Posts Positive Early Data For Its Covid-19 Vaccine CandidateInvestors Business Daily • 11/02/20
Investors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global PactThe Motley Fool • 10/27/20
Covid Report: Regeneron, Moderna, CureVac Up As Possible Coronavirus Cures AdvanceInvestors Business Daily • 09/30/20
Germany Awards $743 Million to BioNTech and CureVac for Coronavirus Vaccine DevelopmentThe Motley Fool • 09/15/20
Got $3,000? These 4 Emerging Coronavirus Vaccine Stocks Look Like a BargainThe Motley Fool • 09/05/20
CureVac Is Promised Up to $298 Million for Coronavirus Vaccine Development by GermanyThe Motley Fool • 09/04/20